艾利利利利的lebrikizumab在治疗儿童和青少年严重湿疹方面表现出强的结果,大多数患者看到了明显的皮肤改善和缓解. Eli Lilly's lebrikizumab showed strong results in treating severe eczema in children and teens, with most seeing major skin improvement and itch relief.

Elilily宣布,EBGLYSS(Lebrikizumab-lbkz)(一种选择性的IL-13抑制剂)在6个月至18岁的儿童和青少年中度至分量性皮肤炎中,第3阶段AFT-1试验结果是积极的。 Eli Lilly announced positive Phase 3 ADorable-1 trial results for EBGLYSS (lebrikizumab-lbkz), a selective IL-13 inhibitor, in children and teens aged 6 months to 18 with moderate-to-severe atopic dermatitis. 在第16周,63%实现了至少75%的皮肤改善(EASI-75),44%的皮肤干净或几乎干净(IGA 0,1),35%报告显著缓解了痒,优于安慰剂。 At week 16, 63% achieved at least 75% skin improvement (EASI-75), 44% had clear or almost clear skin (IGA 0,1), and 35% reported significant itch relief, outperforming placebo. 与先前的数据一致,该药物的种植效果良好,没有新的安全关切。 The drug was well-tolerated with no new safety concerns, consistent with prior data. 外皮性皮炎影响大约960万美国儿童,其中三分之一患有中度至严重疾病。 Atopic dermatitis affects about 9.6 million U.S. children, with one-third having moderate-to-severe disease. 预计将在2026年晚些时候从Adable-2扩展研究获得补充数据。 Additional data from the ADorable-2 extension study are expected later in 2026.